lopinavir + ritonavir + lamivudine

This is a fixed-dose combination of three antiretroviral drugs used in the treatment of HIV infection. Lopinavir and ritonavir are both protease inhibitors, with ritonavir primarily serving as a pharmacokinetic booster to increase plasma levels of lopinavir by inhibiting its metabolism via CYP3A enzymes. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase, thereby blocking viral replication. This combination is used as part of antiretroviral therapy regimens, particularly in pediatric populations or where other first-line options are not available or appropriate[1][5][7]. The regimen has demonstrated non-inferior efficacy compared to standard triple therapy regimens and offers simplified dosing for improved adherence[3][9].

Brand names

Kaletra

Other names

lopinavir/ritonavir/lamivudineLPV/r/3TCLPV/r + 3TC